• This record comes from PubMed

MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response

. 2016 Jun ; 37 (6) : 7719-27. [epub] 20151221

Language English Country United States Media print-electronic

Document type Journal Article

Links

PubMed 26692101
DOI 10.1007/s13277-015-4654-x
PII: 10.1007/s13277-015-4654-x
Knihovny.cz E-resources

Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor. Despite radical surgery and radiotherapy supported by chemotherapy, the disease still remains incurable with an extremely low median survival rate of 12-15 months from the time of initial diagnosis. The main cause of treatment failure is considered to be the presence of cells that are resistant to the treatment. MicroRNAs (miRNAs) as regulators of gene expression are involved in the tumor pathogenesis, including GBM. MiR-338 is a brain-specific miRNA which has been described to target pathways involved in proliferation and differentiation. In our study, miR-338-3p and miR-338-5p were differentially expressed in GBM tissue in comparison to non-tumor brain tissue. Overexpression of miR-338-3p with miRNA mimic did not show any changes in proliferation rates in GBM cell lines (A172, T98G, U87MG). On the other hand, pre-miR-338-5p notably decreased proliferation and caused cell cycle arrest. Since radiation is currently the main treatment modality in GBM, we combined overexpression of pre-miR-338-5p with radiation, which led to significantly decreased cell proliferation, increased cell cycle arrest, and apoptosis in comparison to irradiation-only cells. To better elucidate the mechanism of action, we performed gene expression profiling analysis that revealed targets of miR-338-5p being Ndfip1, Rheb, and ppp2R5a. These genes have been described to be involved in DNA damage response, proliferation, and cell cycle regulation. To our knowledge, this is the first study to describe the role of miR-338-5p in GBM and its potential to improve the sensitivity of GBM to radiation.

See more in PubMed

J Cell Biol. 2012 Jan 9;196 (1):29-36 PubMed

Mol Cell Biochem. 2015 Jan;398(1-2):115-22 PubMed

Tumour Biol. 2013 Aug;34(4):1969-78 PubMed

Cancer Res. 2011 Sep 15;71(18):5945-9 PubMed

Carcinogenesis. 2014 Dec;35(12):2756-62 PubMed

FEBS Lett. 2013 Nov 15;587(22):3729-37 PubMed

Toxicology. 2015 May 4;331:57-65 PubMed

J Neurosci. 2008 Nov 19;28(47):12581-90 PubMed

J Mol Med (Berl). 2010 Oct;88(10 ):1041-53 PubMed

Mol Oncol. 2014 Dec;8(8):1603-15 PubMed

Cancer Biol Ther. 2011 Sep 15;12(6):477-83 PubMed

Nat Rev Genet. 2009 Oct;10(10):704-14 PubMed

Acta Neuropathol. 2007 Aug;114(2):97-109 PubMed

Radiother Oncol. 2011 Jan;98(1):1-14 PubMed

J Biol Chem. 1998 Mar 6;273(10):5858-68 PubMed

Cancer Res. 2015 Oct 15;75(20):4416-28 PubMed

Cell Death Differ. 2006 Jul;13(7):1238-41 PubMed

J Biol Chem. 2015 Mar 13;290(11):7141-50 PubMed

Cell Res. 2008 Jan;18(1):134-47 PubMed

Expert Rev Neurother. 2011 Apr;11(4):509-18 PubMed

Nucleic Acids Res. 2002 Jan 1;30(1):207-10 PubMed

Cancer Invest. 2012 Jan;30(1):48-56 PubMed

Trends Biochem Sci. 2003 Nov;28(11):573-6 PubMed

BMC Cancer. 2008 Oct 22;8:304 PubMed

Cancer Res. 2012 Dec 15;72(24):6414-24 PubMed

J Radiat Res. 2004 Mar;45(1):53-60 PubMed

N Engl J Med. 2005 Mar 10;352(10 ):987-96 PubMed

Traffic. 2014 Jul;15(7):749-61 PubMed

Biochemistry (Mosc). 2013 Apr;78(4):325-34 PubMed

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...